Key Highlights
- A July 2026 board reset appointed a new chief financial officer and chair, with directors paid mainly in share Options to cut cash costs.
- Incanthera acquired the énielle Swiss skincare Brand in June 2026 for up to 54,000,000 shares and no cash, alongside a £250,000 convertible Loan facility.
- Skin+CELL, its flagship direct-to-consumer range, had sold only 177 units for £12,400 of Revenue since its August 2025 launch, against a 100,000-unit stock plan.
- FY March 2025 accounts carried a going-concern material uncertainty, with year-end cash of just £80,000 and an operating loss of £1.997m.
- Cash fell further to £215,000 by 30 September 2025, though the board said it did not anticipate needing near-term fundraising.
July board reset: new chair, new CFO and pay switched to options
On 13 July 2026 Incanthera announced board changes completing the restructuring begun in June. Laura Brogden, with the company since its 2010 spin-out from the University of Bradford, became executive chief financial officer. Werner Bürki, a former chief executive of the Swiss stock exchange, joined as a non-executive director, and Caroline Murray, a director since February 2022 with a big-pharma background, was named non-executive chair.
The more telling part of the announcement concerned costs. The company is targeting "a significant reduction in operational costs driven also by reducing cash compensation by at least 50%", with board members paid "mainly, and in most cases, exclusively" in share options until the Business reaches profitability.
That followed the pivotal 4 June 2026 corporate update. Stuart Robertson was appointed chief executive, Dr Simon Ward moved from CEO to chief scientific officer, and the executive chairman stepped down. Incanthera simultaneously agreed to acquire the énielle skincare brand from a company connected to Robertson, for up to 54,000,000 new shares at 2p and no cash: 13,793,800 shares were issued immediately, giving the vendor 9.09% of the company, with 40,206,200 deferred shares dependent on performance criteria. Robertson also provided a £250,000 two-year convertible loan facility, convertible at 2p, with £100,000 drawn at once. The shares reportedly jumped 41% to 1.85p that day, a gain since unwound.
From cancer therapeutics to protect-by-day, repair-by-night
Incanthera (LSE:INC, quoted on the Aquis Growth Market) began life as a dermatology and oncology therapeutics developer using formulation technology to deliver active compounds to targeted sites in the skin. Its focus has since narrowed to consumer skincare; in March 2025 it ended a pharmaceutical agreement to concentrate on Skin+CELL.
Skin+CELL launched direct to consumer in August 2025. Built around bioactive B3, an activated form of niacinamide, the range spans face, body and hand creams, a serum and an eye cream, made in Switzerland; an initial 100,000 units were produced.
The énielle Acquisition adds a natural and organic Swiss brand with lectin-based daytime formulations, which the June announcement said had absorbed around £3m of cumulative Investment and came with more than 15,000 manufactured serum units, roughly 6,000 of them finished goods. Management intends to sell the two ranges as a single "protect by day, repair by night" routine through direct-to-consumer, premium retail, subscription and wholesale channels, with a bioactive SPF range in the pipeline.
Financials: minimal revenue, widening losses, cash of £215,000
The most recent audited figures cover the year to 31 March 2025. Revenue was nil (FY24: nil), the operating loss widened to £1.997m from £1.380m, and the loss before tax was £1.997m against £1.474m. Basic loss per share was 1.77p (FY24: 1.90p). Year-end cash was just £80,000, although net Assets improved to £1.153m from a £565,000 Deficit after a £2.6m investment round and £732,000 of Warrant exercises; a further £508,000 was raised at 3.5p in June 2025. The auditor flagged a material uncertainty over going concern, the directors noting that the untested direct-to-consumer model "represents a considerable inherent uncertainty".
Unaudited interims for the six months to 30 September 2025 showed the company's first revenue: £6,000, with Gross Profit of £5,000. The operating loss rose to £888,000 from £695,000, loss per share was 0.69p (H1 FY25: 0.57p) and cash fell to £215,000 from £1.058m a year earlier.
A 31 March 2026 commercial update was candid. Skin+CELL had sold 177 units since launch for £12,400 of revenue, or £20,300 at full retail price before discounts, far below the plan to shift the entire 100,000-unit stock by the March 2026 year end. The then-CEO said "the pace of retail sales through the DTC is not at the level we expected". The board said it did not "currently anticipate needing to raise near-term funding" and that directors would support the company if required, as the June Facility later confirmed. Results for the year to 31 March 2026 are still to come.
What could move INC next
The FY26 results, expected around the end of September 2026, will reveal the closing cash position and the auditor's updated going-concern view. Beyond that, the key catalyst would be a first bulk or wholesale order: the March update mentioned discussions with three parties in Europe, Asia and the Middle East, none yet finalised. A prospective licensee is running a randomised controlled study, at its own cost, of its product combined with Skin+CELL. The énielle relaunch, progress on the SPF range and any release of the 40.2m deferred consideration shares, which would signal performance hurdles being met, are also worth tracking.
Risks investors should watch
Funding is the overriding risk. Cash was £215,000 at 30 September 2025, losses have run at roughly £1.5m to £2m a year, and the only new money disclosed since is the £250,000 facility, £100,000 of it drawn. With the shares at around 1.15p, below the 2p conversion price of the loan and the 2p issue price of the énielle shares, any fresh raise could be heavily dilutive; option-based board pay and the facility's 29.9% anti-dilution clause add to the overhang.
Governance deserves scrutiny: the chief executive is simultaneously the vendor of énielle, the company's lender and a beneficial holder of 15.9m shares. Commercial execution is unproven, with 177 units sold against a 100,000-unit target and substantial inventory at risk of ageing. Liquidity on Aquis is thin and the Market Capitalisation is below £2m.
Outlook
Incanthera enters the autumn with a new Leadership team, two brands, a stripped-back cost base and a mandate to sell through wholesale channels rather than rely on influencer-led online sales. Whether that qualifies it as a sleeper depends on evidence that has not yet appeared: a bulk order, a licensing deal or a step-change in monthly sales. The FY26 results will show how much runway the reset has bought and whether the going-concern language has eased or hardened. Until then, INC is a product platform in search of its first meaningful customer.






Please wait processing your request...